VFX.AX stock fell 20.25% intraday on 05 Mar 2026, trading at A$0.063 as sellers accelerated on heavy volume. The drop pushed volume to 67,444.00 shares versus an average of 12,809.00, a relative volume of 5.27, signalling outsized trading. Visionflex Fpo (VFX.AX) is listed on the ASX in Australia and operates in the Healthcare sector. Investors are monitoring technical oversold signals and the company’s fragile fundamentals after weak trailing metrics and negative EPS, while short-term support sits near A$0.05

Intraday price action: VFX.AX stock plunge and drivers

The key intraday move: VFX.AX stock opened at A$0.070 and hit a day low of A$0.063, down A$0.016 from yesterday. Trading volume reached 67,444.00 shares, five times the average, indicating a sell-off driven by sentiment and liquidity moves. No formal earnings announcement was posted; the decline appears driven by technical flows and low market cap stock volatility.

Trading liquidity and volatility for VFX.AX stock

Visionflex shows low market capitalisation at A$5,453,430.00 and only 86,562,381.00 shares outstanding. The stock’s 50-day average price is A$0.0951 and 200-day average is A$0.10668, underlining the downtrend. Relative volume of 5.27 magnifies intraday moves and increases short-term liquidity risk for traders. Expect wider spreads and fast intraday swings in ASX trading.

Fundamentals and valuation: why VFX.AX stock looks weak

Visionflex reports EPS -A$0.02 and a trailing PE of -3.15, reflecting negative earnings. Key ratios show price-to-sales 1.17 and negative book value per share, with current ratio 0.88, signalling short-term liquidity strain. Enterprise value to sales is 1.30, but operating cash flow per share is -0.04697, and free cash flow per share is -0.04739, pointing to persistent cash burn. These fundamentals help explain the market’s cautious reaction.

Technical setup and levels: VFX.AX stock oversold but risky

Technicals are sharply bearish. RSI sits at 21.38 (oversold) and ADX is 31.32 indicating a strong trend. Bollinger middle band is A$0.09 with lower band at A$0.07. Immediate support is near A$0.05 (year low), with resistance at A$0.09 and A$0.11. Short-term traders should watch for a relief bounce but expect high volatility and low liquidity around these levels.

Meyka AI grading and model forecasts for VFX.AX stock

Meyka AI rates VFX.AX with a score of 66.76 out of 100 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly A$0.09, quarterly A$0.20, and yearly A$0.38013. Compared with the current price A$0.063, the yearly projection implies an implied upside of 503.24%. Forecasts are model-based projections and not guarantees.

Risks and opportunities in the ASX healthcare context

Downside risks include negative cash flow, thin market cap, and operational leverage in healthcare services. Sector peers in Healthcare trade with higher liquidity and stronger margins. Opportunity exists if Visionflex secures recurring telehealth contracts or improves cash flow; a successful contract could push the stock toward short-term resistance at A$0.20. Position sizing and risk limits are essential given volatility.

Final Thoughts

VFX.AX stock’s intraday fall to A$0.063 on 05 Mar 2026 highlights heightened short-term risk from low liquidity and weak fundamentals. Technical indicators are oversold, which can attract speculative buyers, but operating cash flow per share of -0.04697 and negative EPS make a sustained recovery uncertain. Meyka AI’s forecast model projects a yearly target of A$0.38013, implying a potential upside of 503.24% from the current price; this represents a model-based scenario, not a guarantee. Near-term realistic targets are support A$0.05 and resistance at A$0.09–A$0.11 on the ASX. Given the B HOLD grade from Meyka AI, traders should treat VFX.AX as high risk, size positions conservatively, and watch for company updates or contract wins that could materially change the outlook. For further company detail see the official Visionflex site and ASX quote

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.